Overview

A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

Status:
Completed
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety, immunogenicity and pharmacodynamic profiles of BCD-264 and Darzalex following a single intravenous infusion in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Biocad
Treatments:
Daratumumab